These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 2836182

  • 1. Effects of corticotropin-releasing factor (CRF) on aldosterone and 18-hydroxycorticosterone in essential hypertension and primary aldosteronism.
    Miyamori I, Yasuhara S, Matsubara T, Okamoto S, Ikeda M, Koshida H, Morise T, Takeda Y, Takeda R, Vecsei P.
    Endocrinol Jpn; 1987 Dec; 34(6):809-19. PubMed ID: 2836182
    [Abstract] [Full Text] [Related]

  • 2. Altered responses of plasma 18-hydroxycorticosterone and aldosterone to angiotensin II and adrenocorticotropin in patients with a 18-hydroxycorticosterone-producing tumor.
    Uchida K, Kigoshi T, Iwasaki R, Morimoto S.
    Jpn J Med; 1989 Dec; 28(4):446-51. PubMed ID: 2554039
    [Abstract] [Full Text] [Related]

  • 3. Dose-response relationships between plasma adrenocorticotropin (ACTH), cortisol, aldosterone, and 18-hydroxycorticosterone after injection of ACTH-(1-39) or human corticotropin-releasing hormone in man.
    Oelkers W, Boelke T, Bähr V.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):181-6. PubMed ID: 2826525
    [Abstract] [Full Text] [Related]

  • 4. Dopamine reduces aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism.
    Witzgall H, Lorenz R, von Werder K, Weber PC.
    Clin Sci (Lond); 1985 Mar; 68(3):291-9. PubMed ID: 3882312
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pituitary peptides other than ACTH may not be aldosterone secretagogue in primary aldosteronism.
    Miyamori I, Koshida H, Matsubara T, Soma R, Takasaki H, Okamoto S, Takeda R.
    Exp Clin Endocrinol; 1990 Aug; 95(3):323-9. PubMed ID: 2174003
    [Abstract] [Full Text] [Related]

  • 7. Effects of corticotropin-releasing factor (CRF) on aldosterone and 18-hydroxycorticosterone secretion.
    Maser-Gluth C, Toygar A, Schaz K, Vecsei P.
    Clin Exp Hypertens A; 1984 Aug; 6(10-11):2097-100. PubMed ID: 6099779
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Time course of plasma corticosterone, 18-hydroxycorticosterone and aldosterone concentrations following CRF administration in the rat. A phase of corticosterone inhibition.
    Maser-Gluth C, Toygar A, Vecsei P.
    Life Sci; 1984 Aug 20; 35(8):879-84. PubMed ID: 6090854
    [Abstract] [Full Text] [Related]

  • 10. The prediction of anatomical morphology of primary aldosteronism using serum 18-hydroxycorticosterone levels.
    Kem DC, Tang K, Hanson CS, Brown RD, Painton R, Weinberger MH, Hollifield JW.
    J Clin Endocrinol Metab; 1985 Jan 20; 60(1):67-73. PubMed ID: 3964794
    [Abstract] [Full Text] [Related]

  • 11. The constant plasma 18-hydroxycorticosterone to aldosterone ratio: an expression of the efficacy of corticosterone methyloxidase type II activity in disorders with variable aldosterone production.
    Kater CE, Biglieri EG, Rost CR, Schambelan M, Hirai J, Chang BC, Brust N.
    J Clin Endocrinol Metab; 1985 Feb 20; 60(2):225-8. PubMed ID: 2981240
    [Abstract] [Full Text] [Related]

  • 12. Plasma beta-endorphin levels in primary aldosteronism.
    Griffing GT, McIntosh T, Berelowitz B, Hudson M, Salzman R, Manson JA, Melby JC.
    J Clin Endocrinol Metab; 1985 Feb 20; 60(2):315-9. PubMed ID: 2981243
    [Abstract] [Full Text] [Related]

  • 13. Determination of urinary 18-hydroxycortisol in the diagnosis of primary aldosteronism.
    Miyamori I, Takeda Y, Takasaki H, Itoh Y, Iki K, Takeda R.
    J Endocrinol Invest; 1992 Jan 20; 15(1):19-24. PubMed ID: 1560187
    [Abstract] [Full Text] [Related]

  • 14. Effect of naloxone on the adrenal cortex in primary aldosteronism.
    Fallo F, Boscaro M, Sonino N, Mantero F.
    Am J Hypertens; 1988 Jul 20; 1(3 Pt 1):280-2. PubMed ID: 2839206
    [Abstract] [Full Text] [Related]

  • 15. Plasma adrenocorticotropin, cortisol, and aldosterone responses to corticotropin-releasing factor: modulatory effect of basal cortisol levels.
    Hermus AR, Pieters GF, Smals AG, Benraad TJ, Kloppenborg PW.
    J Clin Endocrinol Metab; 1984 Jan 20; 58(1):187-91. PubMed ID: 6315759
    [Abstract] [Full Text] [Related]

  • 16. [The role of endogenous dopamine on mineralocorticoids secretion in normal subjects, patients with primary aldosteronism, and idiopathic hyperaldosteronism].
    Shimizu Y.
    Nihon Naibunpi Gakkai Zasshi; 1984 Jan 20; 60(1):1-15. PubMed ID: 6745468
    [Abstract] [Full Text] [Related]

  • 17. Multiple plasma steroid responses to graded ACTH infusions in patients with primary aldosteronism.
    Guthrie GP.
    J Lab Clin Med; 1981 Sep 20; 98(3):364-73. PubMed ID: 6267148
    [Abstract] [Full Text] [Related]

  • 18. Studies of renin activation and regulation of aldosterone and 18-hydroxycorticosterone biosynthesis in hyporeninemic hypoaldosteronism.
    Sowers JR, Beck FW, Waters BK, Barrett JD, Welch BG.
    J Clin Endocrinol Metab; 1985 Jul 20; 61(1):60-7. PubMed ID: 2987296
    [Abstract] [Full Text] [Related]

  • 19. The effect of ovine corticotropin-releasing factor on catecholamine, vasopressin, and aldosterone secretion in normal man.
    Conaglen JV, Donald RA, Espiner EA, Livesey JH, Nicholls MG.
    J Clin Endocrinol Metab; 1984 Mar 20; 58(3):463-6. PubMed ID: 6319453
    [Abstract] [Full Text] [Related]

  • 20. Response of aldosterone and 18-hydroxycorticosterone to angiotensin II in normal subjects and patients with essential hypertension, Conn's syndrome, and nontumorous hyperaldosteronism.
    Fraser R, Beretta-Piccoli C, Brown JJ, Cumming AM, Lever AF, Mason PA, Morton JJ, Robertson JI.
    Hypertension; 1981 Mar 20; 3(3 Pt 2):I87-92. PubMed ID: 7262982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.